KT-621 for Healthy Participants

Lincoln, NE

Phase 1

Recruiting

Research Sponsored by Kymera Therapeutics, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Participants aged 19 to 55 years with specified weight and BMI criteria

Be between 18 and 65 years old

Must not have

Clinically relevant surgical history excluding prior appendectomy or cholecystectomy

Acute GI symptoms at Screening or admission to the CRU

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from enrollment through the safety follow-up visit on either day 14 (sad) or day 38 (mad)

Summary

"This trial is testing a new drug called KT-621 on healthy adult men and women to see how safe it is, how the body processes it, and how it affects the body at different doses."

See full description

Who is the study for?

This trial is for healthy adults aged 19 to 55 who can follow study procedures and agree to use contraception. Participants must have a normal weight and BMI, no recent substance abuse, no significant health issues or abnormal lab results that could affect the study.Check my eligibility

What is being tested?

The trial tests KT-621, a new drug taken by mouth, against a placebo in healthy people. It aims to understand how safe it is and how the body processes it when given once or multiple times at different doses.See study design

What are the potential side effects?

Since this is a first-in-human study of KT-621, potential side effects are not yet fully known but will be closely monitored throughout the trial. Common side effects may include typical reactions seen with oral medications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 19 and 55 years old and meet the specified weight and BMI criteria.

show original

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have had surgery in the past, but not for appendix or gallbladder removal.

show original

Select...

I have acute stomach or intestinal symptoms.

show original

Select...

I have previously received KT-621 in this study.

show original

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from enrollment through the safety follow-up visit on either day 14 (sad) or day 38 (mad)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from enrollment through the safety follow-up visit on either day 14 (sad) or day 38 (mad)

This trial's timeline: 3 weeks for screening, Varies for treatment, and from enrollment through the safety follow-up visit on either day 14 (sad) or day 38 (mad) for reporting.